—

Revolution Medicines Inc (RVMD) — the peer cohort

As of 2026-11-03 — scores re-bake nightly. Cohort = shared Closelooknet index membership first, then sector. Diary readings, not advice.

Revolution Medicines Inc ranks 7 of 7 in its cohort on the Closelooknet composite (29/100) — the cohort is led by Halozyme Therapeutics Inc at 73/100.

NameCompositeMomentumQualityValuationSignalOff 52w high
RVMD Revolution Medicines Inc 29 75 2 — info 13.4%
HALO Halozyme Therapeutics Inc 73 97 94 38 ok 4%
ARGX.BR Argen-X 64 74 75 29 info 14.7%
ONC BeOne Medicines AG 64 83 64 30 info 8.7%
UCB.BR UCB SA 64 71 71 44 info 4.1%
ARGX argenx NV ADR 63 72 74 29 info 16%
REGN Regeneron Pharmaceuticals Inc 62 89 71 48 watch 1.3%

Scores are relative readings across the Closelooknet coverage universe — methodology in the company-scoring explainer. Signal lights come from the nightly signal board.

FAQ · from the current data · as of 2026-11-03

Quick answers

Who are Revolution Medicines Inc's peers in the Closelooknet universe?

The cohort is drawn from shared Closelooknet index membership first, then sector: Halozyme Therapeutics Inc (HALO), Argen-X (ARGX.BR), BeOne Medicines AG (ONC), UCB SA (UCB.BR), argenx NV ADR (ARGX), Regeneron Pharmaceuticals Inc (REGN), as of 2026-11-03.

How does RVMD score against its peers?

Revolution Medicines Inc's composite reads 29/100, ranking 7 of 7 in its cohort as of 2026-11-03; the cohort's highest composite is Halozyme Therapeutics Inc at 73/100. Closelooknet scores are research diary readings, not ratings or advice.

Related in the Closelooknet universe

then Biotechnology. Scored names rank on their Closelooknet score; names without one rank on trend state — above or below their 50- and 200-day averages — never on a score they do not carry.